The optimal regimen of brentuximab vedotin for CD30+ cutaneous lymphoma: Are we there yet?
Geller, S., Myskowski, P.L., Kim, Y.H., Moskowitz, A., Horwitz, S.Language:
english
Journal:
British Journal of Dermatology
DOI:
10.1111/bjd.16052
Date:
October, 2017
File:
PDF, 160 KB
english, 2017